Vol. 5 No. 8 (2025)
Reimbursement Recommendations

Dupilumab (Dupixent)

decorative image of the issue cover

Published August 6, 2025

Key Messages

  • Canada’s Drug Agency (CDA-AMC) recommends that Dupixent be reimbursed by public drug plans for the treatment of severe chronic rhinosinusitis with nasal polyposis (CRSwNP) if certain conditions are met.
  • Dupixent should only be covered to treat adults with severe CRSwNP whose bilateral nasal polyps are confirmed endoscopically or by CT scan, who are tolerant and able to continue the use of intranasal corticosteroids (INCS) but have refractory symptoms despite use of an optimized INCS for at least 3 months, and who have persistent symptoms despite adequate recent treatment with systemic corticosteroids (SCS) and/or nasal polyp surgery.
  • Dupixent should only be reimbursed if the patient is under the care of a physician with expertise in managing severe CRSwNP. When Dupixent is first prescribed, the physician must submit a baseline 22-item Sino-Nasal Outcome Test (SNOT-22) score or endoscopic Nasal Polyp Score (NPS) so that response to treatment can be measured. The cost of Dupixent should be reduced.